A fast-growing pharmaceutical firm wanted to ensure it maintained its reputation as an ethical leader and turned to Interchange for help.
AMCo was keen to be one of the first pharmaceutical companies to implement the new BS 10500 standard for anti-corruption management. Interchange senior consultant Claire Ward, also the non-executive chair of Pharmacy Voice, conducted a thorough analysis of AMCo’s anti-bribery approach against the criteria of BS 10500. We found that AMCo’s systems were already robust and recommended some tweaks and an additional process before guiding AMCo through application for BS 10500 certification.
AMCo achieved the first stage of certification in July 2015 and expects to achieve stage two in October 2015. If successful, AMCo would be the first UK pharmaceutical company to gain BS 10500 certification.
AMCo is committed to bringing its portfolio of niche medicines to patients in more than 100 countries.
What AMCo says
“Interchange’s expertise has ensured that we have the most robust compliance processes possible and the accreditation to prove it.”
Robert Sully, general counsel, AMCo